Cargando…

Gut-liver axis signaling in portal hypertension

Portal hypertension (PHT) in advanced chronic liver disease (ACLD) results from increased intrahepatic resistance caused by pathologic changes of liver tissue composition (structural component) and intrahepatic vasoconstriction (functional component). PHT is an important driver of hepatic decompensa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simbrunner, Benedikt, Mandorfer, Mattias, Trauner, Michael, Reiberger, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815800/ https://www.ncbi.nlm.nih.gov/pubmed/31660028 http://dx.doi.org/10.3748/wjg.v25.i39.5897

Ejemplares similares

Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

Recent advances in the understanding and management of hepatorenal syndrome
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression
por: Jachs, Mathias, et al.
Publicado: (2022)

Portal hypertensive gastropathy is associated with iron deficiency anemia
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension
por: Paternostro, Rafael, et al.
Publicado: (2020)

Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension
por: Raeven, Pierre, et al.
Publicado: (2020)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies
por: Königshofer, Philipp, et al.
Publicado: (2021)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

An impaired pituitary–adrenal signalling axis in stable cirrhosis is linked to worse prognosis
por: Hartl, Lukas, et al.
Publicado: (2023)

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
por: Hartl, Lukas, et al.
Publicado: (2021)

Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19
por: Hartl, Lukas, et al.
Publicado: (2021)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation
por: Hartl, Lukas, et al.
Publicado: (2023)

Low mortality despite temporary liver dysfunction in severe courses of acute hepatitis E
por: Bauer, David J. M., et al.
Publicado: (2022)

The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection
por: Scheiner, Bernhard, et al.
Publicado: (2015)

COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality
por: Hartl, Lukas, et al.
Publicado: (2021)

The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension
por: Seo, Yeon Seok, et al.
Publicado: (2012)

Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence
por: Steininger, Lisa, et al.
Publicado: (2020)

The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis
por: Reiberger, Thomas
Publicado: (2021)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2020)

Ascites and complications: getting to the root of the trouble
por: Mandorfer, Mattias, et al.
Publicado: (2023)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Letter to the Editor: Perioperative Presentation of COVID‐19 in a Liver Transplant Recipient
por: Reiberger,, Thomas, et al.
Publicado: (2021)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease
por: Beer, Lucian, et al.
Publicado: (2020)

Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata
por: Hartl, Lukas, et al.
Publicado: (2022)

Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2022)

The Addition of C‐Reactive Protein and von Willebrand Factor to Model for End‐Stage Liver Disease‐Sodium Improves Prediction of Waitlist Mortality
por: Starlinger, Patrick, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rc3mu8sa19e1195kgt02vd8at7